Kidney International

Papers
(The H4-Index of Kidney International is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Kidney disease is associated with in-hospital death of patients with COVID-191828
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China1241
Acute kidney injury in patients hospitalized with COVID-19986
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases699
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease587
The Novel Coronavirus 2019 epidemic and kidneys441
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease438
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference391
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe367
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases326
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia289
COVID-19 infection in kidney transplant recipients276
The case of complement activation in COVID-19 multiorgan impact254
Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference251
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease242
COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain240
Collapsing glomerulopathy in a COVID-19 patient228
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants194
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference190
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19190
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment184
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy179
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection168
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule165
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease163
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine159
Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference159
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease150
Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients134
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease122
Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference122
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment118
Thrombotic microangiopathy in a patient with COVID-19116
Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients116
Molecular mechanisms and therapeutic targets for diabetic kidney disease114
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial108
The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?107
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients106
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy104
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy102
NELL1 is a target antigen in malignancy-associated membranous nephropathy102
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference100
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains99
Occurrence of severe COVID-19 in vaccinated transplant patients99
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics98
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant97
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients95
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syn93
ANCA glomerulonephritis after the Moderna COVID-19 vaccination92
Visualization of putative coronavirus in kidney92
Rationale and design of the Kidney Precision Medicine Project91
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice90
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease90
Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis90
Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy88
A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19)86
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis85
IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)84
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglob82
Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification81
A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination80
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment80
Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine79
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence78
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis78
Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis78
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease73
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC173
Intestinal microbiota control acute kidney injury severity by immune modulation72
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients72
The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons71
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action71
0.043092966079712